Next-Generation Nanocarriers-Based Nanoformulations for Polycystic Ovary Syndrome (PCOS): A Deep Insight into Clinical and Patents Perspectives

Introduction: Polycystic Ovary Syndrome (PCOS) presents itself as a hormonal and metabolic disorder that affects women during their reproductive years through three primary symptoms. The existing treatments encounter two main obstacles, which include their limited bioavailability and their tendency to produce adverse effects throughout the body. The application of nanotechnology to drug delivery via nanocarriers and nanoformulations offers a solution to existing challenges in the field. Methods: The research team conducted a complete literature review, which examined scientific databases from 1 May 2020 until 1 May 2025. The research team used specific keywords, along with Boolean operators (AND, OR, NOT), to locate relevant peer-reviewed articles, clinical studies, and patents focused on nanocarrier-based nanoformulations for PCOS. Results: The study results demonstrate that nanoformulations that use nanocarrier technology improve PCOS treatment through better drug solubility and bioavailability and precise medication delivery. The combination of multiple medications into one formulation leads to better treatment results while decreasing adverse reactions. The rise in patent applications demonstrates that personalized nanomedicine and hybrid delivery systems are becoming increasingly innovative as they develop. Discussion: A Nanocarrier-based PCOS treatment system provides two advantages through its ability to increase drug solubility and bioavailability while delivering targeted therapies that produce fewer adverse events. Hormonal and metabolic imbalances in patients are effectively treated by multidrug nanoformulations, which achieve better outcomes through their simultaneous multiple actions. The patent system shows that personalized medicine and hybrid nanomedicine approaches have become increasingly innovative. The results from preclinical studies show potential benefits, yet there remain obstacles, including difficulties in scaling operations, determining product safety, and proving linkages between two different fields Conclusion: The development of advanced nanocarriers represents a new medical treatment approach that enables precise medication delivery and better treatment results for patients with PCOS. The increasing volume of clinical research, together with the growing number of patents, indicates high commercial potential, yet additional research on safety and practical applications is required.